Non-small cell lung carcinoma genotype(s)-RET Posts on Medivizor

Selpercatinib for RET-positive non-small-cell lung cancer.

Posted by Medivizor on Oct 23, 2020 in Lung cancer | 0 comments

In a nutshell This trial was carried out to examine the effectiveness and safety of selpercatinib (Retevmo) in treating RET-positive non-small-cell lung cancer (NSCLC). The authors concluded that selpercatinib had good effectiveness and low toxicity in these patients. Some background NSCLC is responsible for 85% of all lung cancer...

Chemotherapy versus EGFR-targeted therapy in non-EGFR-mutated lung cancer

Posted by Medivizor on Jun 21, 2014 in Lung cancer | 0 comments

In a nutshell This article evaluated best treatment options for wild-type epidermal growth factor receptor (EGFR) lung cancer. Specifically, it compared outcomes using EGFR-targeted drugs versus conventional chemotherapy. Some background The EGFR gene is responsible for building a specific protein needed by cancer cells to multiply. Mutations...

Non-small cell lung carcinoma genotype(s)-RET Posts on Medivizor

Selpercatinib for RET-positive non-small-cell lung cancer.

Chemotherapy versus EGFR-targeted therapy in non-EGFR-mutated lung cancer

Categories

Recent Posts

Archives

Non-small cell lung carcinoma genotype(s)-RET Posts on Medivizor

Selpercatinib for RET-positive non-small-cell lung cancer.

Chemotherapy versus EGFR-targeted therapy in non-EGFR-mutated lung cancer

Categories

Recent Posts

Archives

Thanks for your interest in Medivizor

Invalid email